|
|
IL-1R1 |
|
Vaxjo ID |
270 |
|
Vaccine Adjuvant Name |
IL-1R1 |
|
Alternative Names |
Interleukin-1 receptor type 1 |
|
Adjuvant VO ID |
VO_0005758
|
|
Description |
A receptor for IL-1α and IL-1β; mediates inflammation via NF-κB and MAPK pathways. Plays a role in tumor progression, immune evasion, and therapy resistance. |
|
Stage of Development |
Clinical Trial |
|
Host Species for Testing |
Human |
|
Components |
IL-1R1 antagonists could be a novel agent |
|
Structure |
Transmembrane glycoprotein; binds IL-1α/β ligands and activates intracellular signaling. |
|
Function |
IL-1R1 mRNA expression was directly acquired from public datasets, and we also detected IL-1R1 protein expression on tumor microarray by immunohistochemistry. Finally, the associations of IL-1R1 expression with clinical outcomes, immune contexture, and genomic features were analyzed. |
|
Safety |
IL-1R1 expression itself is a biomarker; IL-1R1 antagonists (e.g. anakinra) are generally well-tolerated in other conditions. |
| References |
Zhang et al., 2022: Zhang P, Gu Y, Fang H, Cao Y, Wang J, Liu H, Zhang H, Li H, He H, Li R, Lin C, Xu J. Intratumoral IL-1R1 expression delineates a distinctive molecular subset with therapeutic resistance in patients with gastric cancer. Journal for immunotherapy of cancer. 2022; 10(2); . [PubMed: 35110359].
|
|
